Participated · Series A · Jan 2025

AlloyX builds payments infrastructure that bridges traditional banking with blockchain, enabling businesses to send and receive stablecoin payments and integrate crypto payments. Its platform facilitates currency exchanges and leverages institutional-grade custodial wallets, multi-chain security, and tokenization technology to allow businesses to tokenize real-world assets. The company holds licenses spanning virtual assets, payments, and trusts and serves institutional and retail clients in over 70 countries. AlloyX raised USD10M in a Pre-A funding round led by Solowin Holdings, with participation from Arbitrum Foundation, Offchain Labs, PMT Capital, Ming Capital, Fern Win Capital, Whitecove Capital and Kiln SAS. It intends to use the proceeds to expand operations across the UAE, ASEAN, and Africa to strengthen its position in high-growth regions. The firm offers enterprise-grade solutions aimed at enabling businesses to operate across diverse financial ecosystems. AlloyX operates a DeFi aggregation platform for tokenized credit, enabling protocols, DAOs and institutional investors to build diversified RWA investment strategies. Its core product is a liquid RWA vault and a blended investment vault that combines Credix Finance’s tokenized private credit with tokenized U.S. T‑bills. The team has integrated with nine credit protocols to date, including Credix Finance, Goldfinch and Centrifuge, and is building the industry’s first blended vault with Credix and a tokenized U.S. T‑Bills protocol. AlloyX reports $5 million in total value locked (TVL) and average yields above 18% since inception in 2021. The blended vault taps into more than $530 million in active on‑chain private credit loans and is scheduled to go live in early Q3 2023. The company plans to integrate with additional DeFi protocols and launch more investment vaults later in the year.

Led · Series D · Sep 2018

Miracor Medical Systems GmbH develops and commercializes the Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System, an adjunct therapy designed to reduce myocardial injury and revitalize ischemic myocardium during and after primary PCI procedures. The CE-marked system comprises a reusable console and a single-use catheter and has shown encouraging results on MACE, restenosis rates, and event-free survival in early clinical work. A 10-patient feasibility study in Amsterdam demonstrated successful use of the technology, prompting the company to launch the pivotal RAMSES trial in STEMI patients. Miracor envisions PICSO becoming the standard of care for heart attack treatment, targeting the 30% of acute coronary syndrome cases that suffer suboptimal reperfusion—an addressable market of more than 350,000 patients annually in the U.S. and Europe. Beyond ACS, the technology is being explored for heart failure and cardiac surgery applications. The firm recently secured $3.5 million in non-dilutive funding to support its pivotal study, bolstering its financial position for the next phase of clinical validation.